Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)

被引：0
|
作者：
Strik, A. [1 ]
van de Vrie, W. [2 ]
Bloemsaat-Minekus, J. [3 ]
Nurmohamed, M. [4 ]
Bossuyt, P. [5 ]
Bodelier, A. [6 ]
Rispens, T. [7 ]
van Megen, Y. [3 ]
D'Haens, G. [1 ]
机构：
[1] Acad Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Albert Schweitzer Hosp, Dept Gastroenterol & Hepatol, Dordrecht, Netherlands
[3] Mundipharma Pharmaceut BV, Hoevelaken, Netherlands
[4] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[5] Imelda Hosp, Bonheiden, Belgium
[6] Amphia Hosp Breda Loc Langendijk, Breda, Netherlands
[7] Tytgat Inst Intestinal & Liver Res, AMC, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P724
引用
收藏
页码：S477 / S478
页数：2
相关论文
共 50 条
  • [1] UNCHANGED INFLIXIMAB SERUM CONCENTRATIONS AFTER SWITCHING FROM THE ORIGINATOR INFLIXIMAB TO THE BIOSIMILAR CT-P13 IN PATIENTS WITH QUIESCENT CROHN'S DISEASE: A PROSPECTIVE STUDY
    Strik, Anne S.
    van de Vrie, W.
    Megen, Yvonne
    Minekus, Joanne
    Rispens, Theo
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2017, 152 (05) : S66 - S66
  • [2] Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
    Strik, A.
    van de Vrie, W.
    van Megen, Y.
    Bloemsaat-Minekus, J.
    Rispens, T.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S420 - S420
  • [3] Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Kadivar, Mohammad
    Molin, Daniel
    Angelison, Leif
    Hammarlund, Per
    Olin, Marie
    Torp, Jorgen
    Grip, Olof
    Nilson, Stefan
    Hertervig, Erik
    Lillienau, Jan
    Marsal, Jan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [4] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [5] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [6] SWITCHING FROM INFLIXIMAB ORIGINATOR TO THE BIOSIMILAR (CT-P13) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY ABOUT EFFECTIVENESS AND SAFETY
    Annulli, G.
    Quatraccioni, C.
    Daretti, L. M.
    Antuono, S.
    Guardati, P.
    Calzolari, M.
    Benedetti, A.
    Di Sario, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S134 - S135
  • [7] Efficacy and Safety of Nonmedical Switching From Infliximab Originator to Infliximab Biosimilar CT-P13 in Patients With Inflammatory Bowel Disease, A Single-Center Prospective Study in Japan
    Takeda, Teruyuki
    Takahashi, Atsushi
    Mikumo, Hiroyuki
    Kinjo, Ken
    Yasukawa, Shigeyoshi
    Koga, Akihiro
    Takatsu, Noritaka
    Hisabe, Takashi
    Arima, Hisatomi
    Imakiire, Sou
    Yamauchi, Eri
    Yao, Kenshi
    Hirai, Fumihito
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S11 - S11
  • [8] Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
    Strik, Anne S.
    van de Vrie, Wim
    Bloemsaat-Minekus, Joanne P. J.
    Nurmohamed, Michael
    Bossuyt, Peter J. J.
    Bodelier, Alexander
    Rispens, Theo
    van Megen, Yvonne J. B.
    D'Haens, Geert R.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 404 - 412
  • [9] Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
    Mahmmod, Shaden
    Schultheiss, Johannes P. D.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    Gilissen, Lennard P. L.
    Hoentjen, Frank
    Lutgens, Maurice W. M. D.
    Mahmmod, Nofel
    Van der Meulen-de Jong, Andrea E.
    Smits, Lisa J. T.
    Tan, Adriaan C. I. T. L.
    Oldenburg, Bas
    Fidder, Herma H.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 1954 - 1962
  • [10] Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report
    Strik, Anne S.
    D'Haens, Geert R.
    Lowenberg, Mark
    CLINICAL CASE REPORTS, 2019, 7 (11): : 2049 - 2053
12345